title: A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali.
abstract: Despite considerable experience with single-dose, live, oral cholera vaccine CVD 103-HgR in Asia, Europe, and the Americas, the vaccine had not been evaluated in sub-Saharan Africa or on individuals infected with human immunodeficiency virus (HIV). We therefore conducted a randomized, placebo-controlled, double-blind, cross-over clinical trial in 38 HIV-seropositive (without clinical acquired immunodeficiency syndrome (AIDS)) and 387 HIV-seronegative adults in Mali to assess its safety and immunogenicity. Adverse reactions (fever, diarrhoea and vomiting) were observed with similar frequency among vaccine and placebo recipients. The vaccine strain was not isolated from the coprocultures of any subject. The baseline geometric mean titre (GMT) of serum vibriocidal antibody was significantly lower in HIV-seropositives (1:23) than in HIV-seronegatives (1:65) (P = 0.002). Significant rises in vibriocidal antibody were observed in 71% of HIV-seronegatives and 58% of HIV-seropositives, and in 40% of HIV-seropositives with CD4+ counts below 500 per microliter. Following immunization, the peak vibriocidal GMT in HIV-seronegatives was 1:584 versus 1:124 in HIV-seropositives (P = 0.0006); in HIV-seropositives with CD4+ counts < 500 per microliter, the peak vibriocidal GMT was 1:40 (P = 0.03 versus other HIV-seropositives). CVD 103-HgR was safe in HIV-infected Malian adults, although serological responses were significantly attenuated among HIV-seropositives (particularly in those with CD4+ counts < 500 per microliter) relative to HIV-seronegatives. These results encourage further evaluations of this single-dose, oral cholera vaccine in high-risk populations such as refugees in sub-Saharan Africa.
authors.affiliation: Department of Pediatrics, University of Maryland School of Medicine, Baltimore, USA.
authors.forename: R T
authors.initials: RT
authors.lastname: Perry
authors.forename: C V
authors.initials: CV
authors.lastname: Plowe
authors.forename: B
authors.initials: B
authors.lastname: Koumaré
authors.forename: F
authors.initials: F
authors.lastname: Bougoudogo
authors.forename: K L
authors.initials: KL
authors.lastname: Kotloff
authors.forename: G A
authors.initials: GA
authors.lastname: Losonsky
authors.forename: S S
authors.initials: SS
authors.lastname: Wasserman
authors.forename: M M
authors.initials: MM
authors.lastname: Levine
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood; D022121:Cholera Vaccines / Q000009:adverse effects / Q000276:immunology*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D005334:Fever / Q000209:etiology; D018023:HIV Seronegativity / Q000276:immunology*; D006679:HIV Seropositivity / Q000097:blood / Q000276:immunology*; D006801:Humans; D008297:Male; D008302:Mali; D008875:Middle Aged; D009325:Nausea / Q000209:etiology; D014734:Vibrio cholerae / Q000276:immunology; D014839:Vomiting / Q000209:etiology
chemical_list: D000907:Antibodies, Bacterial; D022121:Cholera Vaccines